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May Measurement Month (MMM) is an annual global blood pressure (BP) screening
campaign aimed at obtaining standardized BP measurements and other relevant
health information from members of the community to increase awareness of ele-
vated BP and the associated risks. Adults (18 years) were recruited through oppor-
tunistic sampling across the various Australian states during May 2019. Three BP
readings were recorded in a standardized manner for each participant, and data on
lifestyle factors and comorbidities were collected. Hypertension was defined as a
systolic BP 140mmHg, or a diastolic BP 90mmHg (according to the MMM protocol)
or taking antihypertensive medication. Multiple imputation was used to estimate
participants’ mean BP where three readings were not available. Of the 2877 partici-
pants, 901 (31.3%) had hypertension of whom 455 (50.5%) were aware of their condi-
tion, and 366 (40.6%) were on antihypertensive medication. Of those taking antihy-
pertensive medication, 54.3% were controlled to <140/90mmHg with the remaining
45.7% of participants inadequately treated. Approximately 74% of treated patients
were on a single antihypertensive medication. The MMM campaign provides an im-
portant platform for standardized compilation of BP data and creation of BP aware-
ness in Australia and other nations worldwide. Data from the 2019 MMM campaign
highlight that BP control rates in Australia remain unacceptably low.
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Introduction
High blood pressure (BP) is one of the most important risk
factors for stroke, coronary heart disease, and chronic kid-
ney disease.1 An estimated 5.6% of Australian adults are af-
fected by one or more of these conditions.2 Based on data
for 2017–18 from the Australian Bureau of Statistics, about
one in three adults (34%) in Australia have confirmed hy-
pertension.1,2 It therefore remains important to further in-
crease BP awareness through the May Measurement Month
(MMM) campaign, initiated in 2017 as a concerted effort of
the International Society of Hypertension (ISH), the World
Hypertension League (WHL), and the High Blood Pressure
Research Council of Australia (HBPRCA), to improve BP con-
trol in Australia and globally.
Methods
The 2019 MMM cross-sectional survey was carried out
throughout the month of May in over 25 sites set up in a
wide range of locations across Australia. The Dobney
Hypertension Centre (DHC) at the University of Western
Australia/Royal Perth Hospital served as the national coor-
dinating centre. Leaders in the hypertension field were
identified in each state and were invited to co-ordinate the
screening efforts locally. All training and promotional
materials were made available via the MMM website. The
campaign was promoted around Australia via various media
channels and social media. BP machines kindly provided by
Omron, Welch Allyn, and A&D, were made available by the
DHC to those sites where machines were required.
Informed consent was obtained from all MMM participants
in line with the MMM protocol.3
Hypertension was defined as a systolic BP of140mmHg
or a diastolic BP of 90mmHg based on the mean of the
second and third BP readings, or in those on antihyperten-
sive medication. The number of patients on treatment who
had BP levels in line with recently recommended BP tar-
gets4,5 was also calculated. Individuals taking three or
more antihypertensive medications with uncontrolled BP
or on four or more medications were identified as treat-
ment resistant. All participants with untreated or uncon-
trolled hypertension were provided with evidence-based
diet and lifestyle modification advice and asked to follow-
up with their general practitioner. All data collected were
analysed centrally by the MMM project team and multiple
imputation based on global data3 was performed to impute
the mean of readings two and three where this was
missing.
Results
During MMM 2019, a total of 2877 Australian participants
were screened. The mean age was 43.5 (19.3) years, com-
prising multiple ethnicities including 1785 White partici-
pants (62.0%), 292 from South-East Asia (10.1%), 271 from
South Asia (9.4%), 157 from East Asia (5.5%), 50 Black par-
ticipants (1.7%), 44 Arabic (1.5%), 109 mixed (3.8%), 160
other (5.6%), and 9 of unknown origin (0.3%) with 1654 fe-
male (57.5%) and 1217 male (42.3%) participants. Of all
participants screened, 177 (6.2%) had previously partici-
pated in MMM17 or MMM18, 2588 (90.0%) were new to
MMM, and the status of 112 (3.9%) was unknown. The ma-
jority of screening took place in public places both indoors
(45.4%) and outdoors (14.9%). The remainder of screening
occurred in hospitals or clinics (21.1%), workplace environ-
ments (15.7%), and other sites (2.9%).
A total of 145 participants (5.0%) reported having diabe-
tes, 50 (1.7%) reported a history of myocardial infarction,
44 (1.5%) reported a history of stroke, 83 (2.9%) reported
aspirin usage, and 137 (4.8%) reported statin use. Smoking
was reported by 211 (7.3%) respondents and 902 (31.4%)
reported alcohol consumption once or more per week. The
mean body mass index of respondents was 25.5kg/m2 and
21 (1.3%) of female respondents reported being pregnant
(Supplementarymaterial online, Table S1).
Following imputation, of all the 2877 participants, 901
(31.3%) had hypertension (Table 1). Of those 901 partici-
pants with hypertension, 50.5% were aware of their diagno-
sis, and 40.6% were on antihypertensive medication. Of the
366 participants on antihypertensive medication, 54.3%
had their BP controlled to <140/90mmHg. Of those for
whom the number of medications was known, 74.1% were
taking a single medication, 17.9% two medications, and
8.0% three or more medications. Of all hypertensive partic-
ipants, 22.0% were controlled to <140/90mmHg and 0.8%
had resistant hypertension. After imputation, of the 2865
individuals for whom age and sex were recorded, the mean
BP, standardized for age and sex according to the WHO
world standard population was 124.1/79.5mmHg in those
not on any antihypertensive medications, and 135.1/
85.9mmHg in those on antihypertensive medications. Of
the 901 participants with hypertension, 535 (59.4%) were
untreated.
Discussion
As part of the MMM19 campaign in Australia, 2877 partici-
pants of multi-ethnic background were screened mostly
from the community rather than from hospitals and phar-
macies. The prevalence of hypertension across the
Australian sites was 31.3% (901 participants), which was
similar to the Australian MMM17 and 2018 campaigns
(31.2% and 30.6%, respectively) and global MMM2017,
2018, and 2019 campaigns (34.9%, 33.4%, and 34% respec-
tively).5–7 Almost half of affected participants (49.5%)
were unaware of their increased BP, which was similar to
the MMM 2018 findings from Australia (49.0%).7 Of the 901
participants with hypertension, only 366 (40.6%) were on
BP lowering medication. Of those on treatment only 54.3%
had controlled BP, leaving 45.7% treated participants
uncontrolled, a rate that is substantially higher than the
global rate of 38.3%.5 The MMM findings demonstrate that
elevated BP remains highly prevalent in Australia and that
hypertension control rates remain unacceptably low com-
pared to global rates. This warrants continued efforts to in-
crease BP awareness and emphasis on appropriate BP
management strategies by tackling some of the major con-
tributors to BP elevation including alcohol consumption
and obesity.5–7
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MMM limitations include the selection bias arising from
convenience sampling. Screening predominantly took
place in major cities and may therefore not reflect a repre-
sentative sample of the Australian population.
Furthermore, the assessment of BP was based on a single
set of three readings in a less than ideal environment
thereby potentially increasing the possibility of false posi-
tive results in terms of hypertension diagnosis. The impact
of the dietary and lifestyle advice given to the participants
with elevated BP and the post-survey awareness could not
be assessed in MMM owing to the cross-sectional design of
the study. Nevertheless, despite the above-mentioned lim-
itations the estimates at the national and global level have
been remarkably consistent across the MMM campaigns and
the Australian estimates are in line with the results from
the Australian Bureau of statistics.1 MMM continues to be
one of the most cost-effective means of raising BP aware-
ness worldwide and in Australia.
Supplementary material
Supplementary material is available at European Heart
Journal Supplements online.
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2877 901 (31.3%) 455 (50.5%) 366 (40.6%) 199 (54.3%) 199 (22.0%)
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